[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646621":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":57,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":28,"enrollmentInfo":75,"targetDuration":28,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":88,"whyStopped":28,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Empiric (Immediate) Antibiotic Treatment","EXPERIMENTAL","Antibiotic Protocol. For participants in the empiric Rx arm, we will choose an antibiotic with consideration of patient reported allergies, current medications and current Infectious Disease Society of American (IDSA) guidelines. If there is a contraindication to the first antibiotic on the list they will progress to the next option until a suitable selection is achieved.",[13],"Drug: Antibiotics",{"label":15,"type":10,"description":16,"interventionNames":17},"Culture-directed Antibiotic Treatment","Participants will be directed to refrain from taking antibiotics until results of urine culture are reported, which is expected within 48-72h.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Urinalysis-directed Antibiotic Treatment","Participants will be directed to refrain from taking antibiotics until results of urinalysis reported, which is expected within 12-24 hours",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Antibiotics","Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim\u002Fsulfamethoxazole 875\u002F125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days",[15,9,19],null,[30],{"name":31,"affiliation":5,"role":32},"Megan Bradley, MD, MSc","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":28,"email":38},"Megan S Bradley, MD MSc","CONTACT","412-641-7850","bradleym4@upmc.edu",[40],{"facility":41,"status":28,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"UPMC-Magee Womens Hospital","Pittsburgh","Pennsylvania","15213","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-79.99589,40.44062,{"lat":51,"lon":50},[54,56],{"name":55,"role":36,"phone":37,"phoneExt":28,"email":38},"Megan S Bradley, MD, MSc",{"name":31,"role":32,"phone":28,"phoneExt":28,"email":28},{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"SPONSOR_INVESTIGATOR","Megan Bradley","Associate Professor",[62],{"name":63,"class":64},"American Association of Obstetricians and Gynecologists Foundation (AAOGF)","UNKNOWN","100646621","phase-3-precision-management-of-urinary-tract-symptoms-in-older-women-100646621",false,"NCT07686055","Precision Management of Urinary Tract Symptoms in Older Women","Precision Management of Urinary Tract Symptoms in Older Women: A Randomized Trial to Reduce Overtreatment","GUIDE-UTI","Inclusion Criteria:\n\n* Female biologic Sex\n* Age ≥65 years old\n* History of recurrent UTI per patient report of greater than 2 UTIs in the last 6 months or 3 UTIs in the last year\n* Patient reported UTI defined as:\n\n  * Dysuria, increased urinary urgency\u002Ffrequency and\u002For suprapubic pain\n\nExclusion Criteria:\n\n* Male biologic sex\n* Age \\\u003C65 years old\n* History of augmentation cystoplasty or cystectomy\n* Currently performing clean intermittent self-catheterization\n* Current indwelling foley catheter\n* Urinary tract instrumentation (i.e., cystourethroscopy, foley catheter placement) in the last 30 days\n* Undergoing treatment for malignancy\n* History of either confirmed or patient reported pyelonephritis and\u002For urosepsis\n* Cirrhosis and\u002For end stage liver disease\n* Chronic kidney disease with most recent estimated glomerular filtration rate \\\u003C50 ml\u002Fmin\n* Dementia and\u002For currently reside in skilled nursing facility\n* Current high-dose chronic steroids (\\>20mg\u002Fday of prednisone)\n* Previous solid organ transplant\n* Provider concern for pyelonephritis and\u002For sepsis (i.e., fevers)\n* Unwilling or unable to comply with study procedures (including ability to complete electronic questionnaires)","FEMALE","65 Years",{"count":76,"type":77},90,"ESTIMATED","INTERVENTIONAL",[80],"PHASE3","This project aims to improve the diagnosis and management of urinary tract symptoms in older women by comparing three common treatment strategies-empiric antibiotics, urinalysis-guided therapy, and culture-directed care-in a randomized trial. By integrating patient-reported outcomes, laboratory data, the study will identify which patients benefit from antibiotics and which can safely avoid them. Findings will inform precision care strategies and promote antibiotic stewardship while improving symptom outcomes and quality of life in this high-risk population.",[83],"Urinary Tract Infection (Diagnosis)",[85,86,87],"Urinary Tract Infection","Women","Older","NOT_YET_RECRUITING","2026-06-30",{"date":91,"type":92},"2026-07-07","ACTUAL",{"date":94,"type":77},"2026-07-14",{"date":96,"type":77},"2027-02-14",{"name":59,"class":6},1]